Compass-logo-RGB-outlines.png
Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans
March 30, 2022 08:00 ET | Compass Therapeutics
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based therapeutics to...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 21, 2022 08:00 ET | Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
Imara-Logo-Color-RGB.jpg
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
January 25, 2022 07:00 ET | Imara, Inc.
Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched...
Compass-logo-RGB-outlines.png
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
January 20, 2022 08:30 ET | Compass Therapeutics
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
HIMALAYA INVESTS IN GENBIO TO PROMOTE GLOBAL WELLNESS; PLANS “FOMO CAN”
December 13, 2021 06:15 ET | Himalaya Technologies, Inc.
Chicago, IL, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Himalaya Technologies, Inc. (OTC: HMLA; “Himalaya”) and GenBio, Inc. (“GenBio”) have agreed to a 19.9% share exchange and a collaboration on a range of...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PolarityTE, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTE
October 07, 2021 17:45 ET | The Rosen Law Firm PA
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of PolarityTE, Inc. (NASDAQ: PTE) between April 30, 2020 and...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A RESPECTED AND LEADING FIRM, Encourages PolarityTE, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – PTE
September 29, 2021 16:08 ET | The Rosen Law Firm PA
NEW YORK, Sept. 29, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
20170406 Telix Logo.png
FDA Approves Phase II Kidney Cancer Therapy Study
September 13, 2021 18:41 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug...
LOGO.jpg
QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
August 25, 2021 09:00 ET | QSAM Biosciences Inc.
Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment...
BioStem Technologies Main Logo.jpg
BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.
July 27, 2021 09:00 ET | BioStem Technologies, Inc.
Pompano Beach, Fl., July 27, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing...